Humana Reports Mixed Q3 Results with Revenue Growth but Declining Net Income

Humana Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a mixed performance compared to the previous fiscal period. For the three months ended September 30, 2025, the company generated total revenues of $32.6 billion, an increase of 11.1% from $29.4 billion in the same period of 2024. The growth was primarily driven by a 9.9% rise in premiums, totaling $30.7 billion, and a significant 45.1% increase in services revenue, which reached $1.6 billion. However, net income attributable to Humana decreased to $195 million, or $1.62 per diluted share, down from $480 million, or $3.98 per diluted share, in the prior year, largely due to impairment charges and a loss on the sale of a business.

In the nine-month period, Humana's total revenues increased to $97.1 billion, up 9.7% from $88.5 billion in 2024. Premiums for the nine months rose by 9.0% to $91.9 billion, while services revenue also saw a notable increase of 32.7%, reaching $4.3 billion. The company reported net income of $1.98 billion, or $16.43 per diluted share, compared to $1.90 billion, or $15.72 per diluted share, in the previous year. The year-to-date results were positively impacted by favorable prior-period medical claims reserve development, which contributed to a lower benefit ratio.

Operationally, Humana's total medical membership decreased by 8.3% year-over-year to approximately 14.99 million members as of September 30, 2025. This decline was primarily attributed to a reduction in individual Medicare Advantage membership, which fell by 7.5%. Conversely, the company experienced growth in its state-based contracts and Medicare stand-alone PDP memberships. The company also reported that approximately 68% of its individual Medicare Advantage members were in value-based relationships, a slight decrease from 70% in the previous year.

Strategically, Humana has been focusing on value creation initiatives, which included workforce optimization and external consulting efforts, resulting in charges of $267 million for the third quarter and $320 million for the nine months ended September 30, 2025. The company also recorded impairment charges of $32 million related to indefinite-lived intangible assets during the nine-month period. Looking ahead, Humana anticipates continued challenges in the Medicare Advantage market, particularly with the impact of regulatory changes and competitive dynamics, but remains committed to enhancing its integrated care delivery model to improve health outcomes and member experiences.